Austin Hsu,Qiming Duan,Daniel S. Day,Xin Luo,Sarah McMahon,Yu Huang,Zachary B. Feldman,Zhen Jiang,Tinghu Zhang,Yanke Liang,Michael Alexanian,Arun Padmanabhan,Jonathan D. Brown,Charles Y. Lin,Nathanael S. Gray,Richard A. Young,Benoit G. Bruneau,Saptarsi M. Haldar

Abstract:Abstract Heart failure with reduced ejection fraction (HFrEF) is associated with high mortality, highlighting an urgent need for new therapeutic strategies. As stress-activated cardiac signaling cascades converge on the nucleus to drive maladaptive gene programs, interdicting pathological transcription is a conceptually attractive approach for HFrEF therapy. Here, we demonstrate that CDK7/12/13 are critical regulators of transcription activation in the heart that can be pharmacologically inhibited to improve HFrEF. CDK7/12/13 inhibition using the first-in-class inhibitor THZ1 or RNAi blocks stress-induced transcription and pathologic hypertrophy in cultured rodent cardiomyocytes. THZ1 potently attenuates adverse cardiac remodeling and HFrEF pathogenesis in mice and blocks cardinal features of disease in human iPSC-derived cardiomyocytes. THZ1 suppresses Pol II enrichment at stress-transactivated cardiac genes and inhibits a specific pathologic gene program in the failing mouse heart. These data identify CDK7/12/13 as druggable regulators of cardiac gene transactivation during disease-related stress, suggesting that HFrEF features a critical dependency on transcription that can be therapeutically exploited.

Targeting transcription in heart failure via CDK7/12/13 inhibition